UK-Singapore Health Fund Will Support Medtech Projects
Developers of diagnostic and digital health tools can apply for joint funding to scale innovations starting in October.
Updated on Oct. 10, 2026 in Healthcare
Live Poll
Do you trust that international healthcare research partnerships will lead to better treatment options in your area?
The National Institute for Health and Care Research (NIHR) and the National Health Innovation Centre (NHIC) Singapore will open the i4i-LeapX funding program on 14th October 2026. This initiative targets late-stage medical technology, diagnostics, and digital health projects requiring cross-border collaboration.
Why it matters
The program addresses shared clinical challenges, such as aging populations and chronic disease burdens, by facilitating international clinical validation. It offers businesses a pathway to meet national health priorities while securing capital for regulatory and real-world evaluation.
The program provides up to £500,000 for UK components and SGD $750,000 for Singapore components, with a project duration spanning 24 months. Eligible technologies include medtech, in vitro diagnostics, and digital health tools.
The players
National Institute for Health and Care Research
The UK government agency responsible for funding health and care research to improve patient outcomes.
National Health Innovation Centre Singapore
A government-supported organization that accelerates the commercialization of health innovations.
The details
Applicants must secure collaborative partnerships across the UK and Singapore to qualify for the initiative. The funding covers essential operational steps for market entry, including clinical validation, regulatory clearance, and real-world evaluation. Projects must align with specific national strategies, notably the UK 10-Year Health Plan and the Singapore Healthier SG framework.
Timeline
14th October 2026: The i4i-LeapX funding opportunity opens for applications.
24 months: The duration of the funded project activities.
Market Landscape
The i4i-LeapX program operationalizes the priorities of the UK 10-Year Health Plan by incentivizing the development of diagnostic tools that address systemic chronic disease needs. This marks a shift toward internationalized funding models for late-stage medical technology development.
Medtech firms should confirm if their cross-border clinical trial data meets the regulatory requirements of both the UK and Singapore markets. Owners must verify that their technology roadmaps align with the specific goals of the UK 10-Year Health Plan and the Healthier SG strategy.
The takeaway
This program provides a strategic opportunity for medtech developers to leverage joint capital for international clinical validation. Operators should evaluate their pipeline readiness for real-world evaluation and health economics requirements before the 14th October 2026 launch.
What happens next
Applications for the i4i-LeapX program open on 14th October 2026.
Further reading
Learn more about evolving standards in our Healthcare section.
Live Poll
Do you trust that international healthcare research partnerships will lead to better treatment options in your area?
